Treatment of Targeted Therapy-Related Fatigue in Patients with CML or GIST: A Single-Case Experimental Design

Treatment of Targeted Therapy-Related Fatigue in Patients with CML or GIST: A Single-Case Experimental Design - Single-Case Experiment in Patients with TTF

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41733

Enrollment

Registered

2014-12-29

Start date

2015-03-26

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeoloid Leukemia Gastro-intestinal stromal tumour

Interventions

Participants will receive CBT for fatigue in addition to usual care. CBT will consist of approximately 14 individual one-hour sessions over a period of 26 weeks. The CBT will be given by trained the

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age of 18 years or above; • Able to speak, read, and write Dutch; • Diagnosed with CML or GIST; • Receiving (chronic) treatment with a tyrosine kinase inhibitor (TKI) for at least 3 months; • Being severely fatigued (CIS fatigue >= 35), without known and treatable somatic causes for fatigue.

Exclusion criteria

Exclusion criteria: • Receiving treatment for a psychiatric disorder

Design outcomes

Primary

Measure	Time frame
Fatigue severity is the primary outcome measure of the proposed SCE.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)